We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
NT-proBNP and echocardiographic parameters in patients with acute heart failure.
AIM: The aim of this study was to analyse the relation between clinical, haemodynamic and X-ray parameters and plasma NT-proBNP level in pts with symptoms of left ventricular dysfunction.
METHODS: The plasma NT-proBNP levels, chest x-ray, transthoracic 2-d and Doppler echocardiography were performed at the time of admission in a group of 96 consecutive patients (mean age 68 +/- 11 years) with symptoms of acute heart failure. NT-proBNP levels were assessed with the use of commercial tests (Roche Diagnostics).
RESULTS: All patients have significant increase in NT-proBNP (8000 +/- 9000 pg/mL vs. controls 90 +/- 80 pg/mL, p < 0.001). The group of all patients has shown a significant increase in cardiothoracic ratio (CTR, 0.6 +/- 0.1, vs. 0.4 +/- 0.1, p < 0.001), left atrium diameter (LAD, 4.4 +/- 0.8 cm, vs.3.5 +/- 0.4 cm, p < 0.01). Left ventricular ejection fraction (LVEF) was decreased (37 +/- 15%, vs. 64 +/- 5%, p < 0.001). In patients with acute heart failure, NT-proBNP significantly correlated with end-systolic and end-diastolic left ventricle diameters, ejection fraction, vena cava inferior diameter and plasma creatinine levels.
CONCLUSION: Increased plasma NT-proBNP level is influenced by the clinical severity of acute heart failure and correlates with LVEF and IVCD. NT-proBNP can serve as a marker for the clinical severity of the disease.
METHODS: The plasma NT-proBNP levels, chest x-ray, transthoracic 2-d and Doppler echocardiography were performed at the time of admission in a group of 96 consecutive patients (mean age 68 +/- 11 years) with symptoms of acute heart failure. NT-proBNP levels were assessed with the use of commercial tests (Roche Diagnostics).
RESULTS: All patients have significant increase in NT-proBNP (8000 +/- 9000 pg/mL vs. controls 90 +/- 80 pg/mL, p < 0.001). The group of all patients has shown a significant increase in cardiothoracic ratio (CTR, 0.6 +/- 0.1, vs. 0.4 +/- 0.1, p < 0.001), left atrium diameter (LAD, 4.4 +/- 0.8 cm, vs.3.5 +/- 0.4 cm, p < 0.01). Left ventricular ejection fraction (LVEF) was decreased (37 +/- 15%, vs. 64 +/- 5%, p < 0.001). In patients with acute heart failure, NT-proBNP significantly correlated with end-systolic and end-diastolic left ventricle diameters, ejection fraction, vena cava inferior diameter and plasma creatinine levels.
CONCLUSION: Increased plasma NT-proBNP level is influenced by the clinical severity of acute heart failure and correlates with LVEF and IVCD. NT-proBNP can serve as a marker for the clinical severity of the disease.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app